Anatara Lifesciences is pleased to release a copy of Anatara CEO, Steve Lydeamore, recent interview with Ky Chow of Proactive Investors Australia about the healthcare company’s renewed focus on human health, targeting the 11% of Australians affected by irritable bowel syndrome (IBS).

Lydeamore says the biotech firm’s dietary supplement is unlike other gut health products at the pharmacy because it seeks to repair lining of the gut.